BeiGene
BGNE
$187.49
Share price
0.29%
Change (1 day)
-2.15%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Earnings for BeiGene (BGNE)
Earnings in 2023 (TTM): -$1.3 B
According to BeiGene 's latest financial reports the company's current earnings (TTM) are -$1.3 B. In 2022 the company made an earning of -$1.79 B a decrease over its 2021 earnings that were of -$1.44 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for BeiGene from 2015 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$1.3 B | -27.78% |
| 2022 | -$1.79 B | 24.39% |
| 2021 | -$1.44 B | -13.21% |
| 2020 | -$1.66 B | 72.69% |
| 2019 | -$0.96 B | 36.01% |
| 2018 | -$0.71 B | 616.83% |
| 2017 | -$98.46 M | -16.53% |
| 2016 | -$0.12 B | 112.96% |
| 2015 | -$55.39 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -$0.22 B | -83.44% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -$20.19 M | -98.44% | 🇺🇸 USA |